Esperion Therapeutics Inc (NASDAQ:ESPR) shares traded up 8.5% during mid-day trading on Tuesday . The company traded as high as $64.88 and last traded at $64.38. 846,539 shares were traded during trading, a decline of 16% from the average session volume of 1,003,047 shares. The stock had previously closed at $59.36.

A number of research analysts have issued reports on the stock. BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 16th. Northland Securities reaffirmed a “buy” rating and set a $72.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Needham & Company LLC raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and upped their price target for the stock from $72.00 to $81.00 in a report on Thursday, December 14th. Chardan Capital reaffirmed a “neutral” rating and set a $75.00 price target (up previously from $20.00) on shares of Esperion Therapeutics in a report on Tuesday, December 5th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $70.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $60.85.

The firm has a market cap of $1,660.00, a PE ratio of -9.38 and a beta of 2.73.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same period in the prior year, the business posted ($0.77) EPS. research analysts forecast that Esperion Therapeutics Inc will post -7.3 EPS for the current year.

In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of the firm’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the sale, the director now directly owns 2,472 shares in the company, valued at $133,117.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 32.50% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Meditor Group Ltd increased its stake in shares of Esperion Therapeutics by 305.5% in the third quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock worth $115,022,000 after purchasing an additional 1,728,935 shares in the last quarter. BB Biotech AG grew its stake in Esperion Therapeutics by 7.5% during the second quarter. BB Biotech AG now owns 1,513,542 shares of the biopharmaceutical company’s stock valued at $70,047,000 after acquiring an additional 105,000 shares in the last quarter. State Street Corp grew its stake in Esperion Therapeutics by 264.6% during the second quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock valued at $69,721,000 after acquiring an additional 1,093,292 shares in the last quarter. FMR LLC grew its stake in Esperion Therapeutics by 2.3% during the second quarter. FMR LLC now owns 1,338,588 shares of the biopharmaceutical company’s stock valued at $61,950,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Discovery Capital Management LLC CT lifted its position in Esperion Therapeutics by 152.9% during the second quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock valued at $44,663,000 after purchasing an additional 583,529 shares during the last quarter. Institutional investors and hedge funds own 92.24% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://theolympiareport.com/2017/12/26/esperion-therapeutics-espr-trading-8-5-higher.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.